- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Top Stock Picks from Analysts
U.S. Pharmaceuticals & Biotech Top Stock Picks from Analysts
Results
445
Companies which are more than 50% undervalued based on analyst price target.
445 companies
Silence Therapeutics
Market Cap: US$236.2m
A biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.
SLN
US$5.00
7D
-11.8%
1Y
-73.1%
OmniAb
Market Cap: US$234.6m
A biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada.
OABI
US$1.63
7D
1.2%
1Y
-58.3%
TriSalus Life Sciences
Market Cap: US$230.4m
Engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers.
TLSI
US$4.62
7D
-1.1%
1Y
4.1%
Atea Pharmaceuticals
Market Cap: US$230.1m
A clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections.
AVIR
US$2.90
7D
-0.7%
1Y
-15.0%
Codexis
Market Cap: US$229.3m
Provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China.
CDXS
US$2.54
7D
3.0%
1Y
-18.6%
Crescent Biopharma
Market Cap: US$229.1m
A biotechnology company, researches and develops cancer therapy candidates.
CBIO
US$11.72
7D
-4.6%
1Y
n/a
Invivyd
Market Cap: US$226.1m
A biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.
IVVD
US$1.16
7D
3.6%
1Y
25.9%
Cabaletta Bio
Market Cap: US$223.2m
A clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases.
CABA
US$2.44
7D
2.5%
1Y
-39.2%
Black Diamond Therapeutics
Market Cap: US$221.5m
A clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors.
BDTX
US$3.89
7D
4.3%
1Y
6.3%
Enanta Pharmaceuticals
Market Cap: US$220.8m
A biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases.
ENTA
US$10.33
7D
-31.9%
1Y
-10.6%
MediWound
Market Cap: US$220.4m
A biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally.
MDWD
US$17.19
7D
-4.3%
1Y
5.4%
Tiziana Life Sciences
Market Cap: US$219.6m
A biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States.
TLSA
US$1.97
7D
-7.3%
1Y
113.7%
Entrada Therapeutics
Market Cap: US$213.3m
A clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases.
TRDA
US$6.00
7D
2.7%
1Y
-63.7%
Caribou Biosciences
Market Cap: US$211.4m
A clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally.
CRBU
US$2.27
7D
-1.3%
1Y
24.7%
Tonix Pharmaceuticals Holding
Market Cap: US$210.4m
A biopharmaceutical company, focuses on developing and commercializing therapeutics to treat and prevent human disease.
TNXP
US$24.00
7D
-3.1%
1Y
66.8%
Milestone Pharmaceuticals
Market Cap: US$206.6m
A biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada.
MIST
US$2.11
7D
3.9%
1Y
38.8%
Sangamo Therapeutics
Market Cap: US$206.0m
A clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States.
SGMO
US$0.68
7D
-2.4%
1Y
-14.9%
Aclaris Therapeutics
Market Cap: US$201.5m
A clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States.
ACRS
US$1.86
7D
-3.1%
1Y
61.7%
SELLAS Life Sciences Group
Market Cap: US$196.9m
A late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.
SLS
US$1.87
7D
19.9%
1Y
48.4%
Protalix BioTherapeutics
Market Cap: US$193.7m
A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
PLX
US$2.43
7D
12.5%
1Y
138.2%
Journey Medical
Market Cap: US$192.9m
Focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
DERM
US$7.33
7D
3.2%
1Y
16.5%
Protara Therapeutics
Market Cap: US$191.4m
A clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases.
TARA
US$4.96
7D
12.5%
1Y
181.8%
Coherus Oncology
Market Cap: US$190.6m
A biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
CHRS
US$1.64
7D
-3.5%
1Y
53.3%
Alto Neuroscience
Market Cap: US$186.6m
Operates as a clinical-stage biopharmaceutical company in the United States.
ANRO
US$6.89
7D
71.8%
1Y
-37.6%
MaxCyte
Market Cap: US$182.3m
A life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally.
MXCT
US$1.71
7D
14.0%
1Y
-54.8%
Corbus Pharmaceuticals Holdings
Market Cap: US$181.7m
A biopharmaceutical company, develops products to defeat serious illness.
CRBP
US$14.83
7D
21.0%
1Y
-21.9%
Avalo Therapeutics
Market Cap: US$176.2m
A clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States.
AVTX
US$13.40
7D
2.9%
1Y
39.1%
Eledon Pharmaceuticals
Market Cap: US$170.1m
Operates as a clinical stage biotechnology company.
ELDN
US$2.84
7D
11.8%
1Y
8.4%
AVITA Medical
Market Cap: US$168.9m
Operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom.
RCEL
US$5.54
7D
3.2%
1Y
-47.0%
Rapid Micro Biosystems
Market Cap: US$167.6m
A life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally.
RPID
US$3.79
7D
14.8%
1Y
321.1%
Genelux
Market Cap: US$166.2m
A clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.
GNLX
US$4.45
7D
4.7%
1Y
77.3%
C4 Therapeutics
Market Cap: US$161.6m
A clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins.
CCCC
US$2.27
7D
1.8%
1Y
-55.9%
Achieve Life Sciences
Market Cap: US$161.0m
A late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
ACHV
US$3.15
7D
3.6%
1Y
-38.7%
Actuate Therapeutics
Market Cap: US$160.0m
A clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States.
ACTU
US$6.98
7D
3.1%
1Y
-2.1%
Pyxis Oncology
Market Cap: US$159.4m
A clinical stage company, engages in the development of therapeutics to treat solid tumors.
PYXS
US$2.57
7D
16.8%
1Y
-24.4%
Citius Oncology
Market Cap: US$157.8m
Focuses on the development and commercialization of innovative targeted oncology therapies.
CTOR
US$1.89
7D
-6.9%
1Y
75.0%